What Flotral Treats: Main Uses and Benefits

Flotral (Alfuzosin) is commonly used to help manage lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), or an enlarged prostate. It is applied in clinical settings that involve symptomatic discomfort and functional strain, offering supportive therapeutic benefit. Flotral is relevant for easing symptoms linked to an enlarged prostate, such as difficulty starting urination (hesitancy), having a weak or slow urine stream, and a frequent or urgent need to urinate. These symptoms cluster into patterns that often require supportive management when they create noticeable functional strain.

The medication assists with managing the irritative and obstructive symptoms of BPH, including urinary frequency, urgency, nocturia, and the sensation of incomplete bladder emptying. This supportive relief may assist with maintaining functional stability and contributes to improved comfort during symptomatic periods.

“Used across domains where additional symptomatic support is needed.”

---

Quick Fact: Relief for Obstructive Symptoms

Flotral helps address symptom clusters that may become disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It is often used during phases when symptoms become more noticeable.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Flotral?

Flotral (alfuzosin hydrochloride) is a prescription medicine whose eligibility is strictly defined by regulatory guidelines to ensure appropriate use and patient safety. Use is primarily indicated for one specific population, and it is prohibited for others due to metabolic or concurrent treatment risks.

---

Approved and Restricted Populations

Population / Condition	Eligibility Status	Key Regulatory Note
Adult Men with BPH	Permitted (Indicated Use)	The only population for which the drug is formally indicated.
Pediatric Patients	Not Established	Safety and efficacy have not been demonstrated; use is not indicated.
Severe Renal Impairment	Conditional Use	Caution is required, particularly when creatinine clearance is less than 30 mL/min.
Females (Pregnancy/Lactation)	Not Indicated	The drug is not indicated for use in women.

---

Absolute Contraindications (Must Not Use)

Flotral is formally contraindicated in several patient groups, meaning use is strictly prohibited under any circumstance:

• Patients with Moderate to Severe Hepatic Impairment (severe liver disease), due to the risk of increased drug concentration in the body.
• Patients taking other Alpha-1 Adrenergic Antagonists (other alpha-blockers), due to the risk of severe, uncontrolled low blood pressure.
• Patients taking Potent CYP3A4 Inhibitors (certain antifungals or antivirals), which can significantly increase alfuzosin levels.
• Patients with Known Hypersensitivity to alfuzosin or any tablet component.

Interactions with other medicines and products

Flotral (alfuzosin) has documented interactions with several classes of medications and substances, impacting both its blood levels and its effect on blood pressure. These interactions are classified by regulatory bodies as either contraindicated (must not be combined) or requiring caution.

---

Contraindicated Combinations

Flotral must not be used concurrently with certain medications due to the risk of severe adverse effects or substantially increased exposure:

• Potent Cytochrome P450 3A4 (CYP3A4) Inhibitors: These drugs, which include ketoconazole, itraconazole, and ritonavir, increase the concentration of alfuzosin in the body, which can increase the risk of adverse reactions. This is a pharmacokinetic interaction.
• Other Alpha-Adrenergic Blocking Agents (Alpha-Blockers): Combining Flotral with other alpha-blockers can lead to an exaggerated decrease in blood pressure (hypotension).

---

Use-with-Caution Combinations

Caution and clinical assessment are necessary when Flotral is co-administered with the following:

• Phosphodiesterase-5 (PDE5) Inhibitors: Co-administration may increase the risk of symptomatic hypotension.
• Antihypertensive Medications and Nitrates: These combinations increase the risk of postural hypotension and fainting (syncope).
• Drugs that Prolong the QT Interval: Flotral should be used cautiously in patients taking these medications.
• Warfarin: Co-administration requires caution.

---

Food and Beverage Interaction

Flotral must be taken with food, at the same meal each day, to ensure proper absorption. Consumption of grapefruit or grapefruit juice should be avoided, as it can interfere with the metabolism of alfuzosin and increase its concentration.

The mechanism of Flotral (alfuzosin) is rooted in its interaction with the autonomic nervous system to modulate muscle tone in the lower urinary tract.

Alfuzosin functions as a competitive antagonist at post-synaptic alpha1-adrenoceptors. These receptors are concentrated on the smooth muscle cells of the prostate, prostatic capsule, and bladder neck. Blocking these receptors prevents the action of norepinephrine, the neurotransmitter that mediates muscle contraction.

This molecular action results in the inhibition of the G q signaling pathway, leading to reduced intracellular calcium ion ( Ca^2+) mobilization. This cellular event induces the relaxation of the smooth muscle tissue, directly addressing the dynamic component of any functional obstruction. The physiological consequence is a decrease in the intrinsic pressure and resistance at the bladder outlet, which lowers the functional obstruction to urine flow. This mechanism modulates resistance driven by muscle tone and does not address the static component (physical prostate volume).

How to Use Flotral

The administration of Flotral (Alfuzosin 10 mg extended-release tablets) follows specific protocols to ensure proper use. This information describes the standardized protocol for its intake.

Flotral is administered orally in the form of a single 10 mg extended-release tablet taken once daily. To ensure consistent drug absorption, the tablet must be taken with food, specifically immediately after the same meal each day.

---

Administration Protocol

Feature	Guideline
Dosing Schedule	One 10 mg tablet taken once daily.
Handling	The tablet must be swallowed whole with sufficient fluid. It must not be chewed, crushed, split, or ground, as this action compromises the extended-release mechanism.
Timing Constraint	Must be taken immediately after the same meal each day.
Missed Dose	If a dose is missed, it should be skipped. The next dose should be taken at the scheduled time with the next meal. A double dose must not be taken.

---

Context and Population Use

Flotral is intended for continuous, long-term use in managing BPH symptoms. It is also utilized in a short-term, fixed regimen of 3 to 4 days when used adjunctively for Acute Urinary Retention. The standard 10 mg once-daily dose applies to older adults and patients with mild to moderate renal impairment. The use of this formulation is not indicated for the pediatric population or for patients with severe hepatic impairment.

Research Evidence / Overview of Studies for Flotral

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Research has explored how Flotral (alfuzosin) has been evaluated in relation to urinary difficulties linked to an enlarged prostate (BPH). Studies have been conducted to monitor changes in urinary flow and how individuals reported their symptoms evolving over time. Findings describe patterns observed in studies related to outcomes reflecting daily functioning and systemic imbalance. Research has examined changes in patient-reported symptoms over defined time intervals, contributing to understanding symptom patterns associated with BPH. Results apply only to the populations studied, and comparative evidence for certain patient groups is lacking.

---

Evidence in Preventing Acute Urinary Retention (AUR) and Related Complications

Flotral was also studied for its potential role in managing or reducing the risk of Acute Urinary Retention (AUR), the sudden inability to pass urine. Research explored whether Flotral was observed to correlate with changes in the incidence of AUR, particularly following certain urinary procedures. Studies also monitored outcomes related to whether patients were able to void the bladder after an AUR episode. Research examined outcomes related to the time until a need for surgical intervention was reported in certain participants. Follow-up durations were limited in some of these studies, meaning long-term effects are not fully established.

---

Evidence in Special Populations

Studies have been used to evaluate Flotral in special populations, including older adults and individuals with pre-existing health conditions (comorbidities). Specifically, research has examined how the medication was processed in patients with varying degrees of mild-to-moderate changes in their liver or kidney function. Research describes how the medication was processed in patients with reduced liver function, noting that it was observed to remain in the system longer in some studies. Data for other groups, such as those with severe kidney impairment, remain insufficient, and subgroup findings are uncertain due to modest sample sizes.

---

What is Still Uncertain About Flotral

The body of evidence still has certain gaps where certainty remains low. Research is ongoing, but studies highlight changes measured during the study period, not definitive answers for all individuals. One key area of uncertainty is the lack of extensive, high-quality comparative evidence directly measuring Flotral against other medications used for BPH. The data are still emerging concerning the long-term patterns observed and the specific factors that may correlate with observed differences in how individual patients report their experience with the medication.

Common questions about Flotral (FAQ)

Q: What is the main difference between Flotral and other drugs that treat the same condition?

Official information describes Flotral (alfuzosin) as belonging to the alpha-blocker class, which is also shared by other treatments for BPH. Alfuzosin is distinct from some other alpha-blockers in its chemical structure and its potential to cause a greater effect on blood pressure. Also, regulatory documents state that alfuzosin is contraindicated (prohibited) in individuals with moderate to severe liver impairment.

Q: Is Flotral used for anything besides prostate issues?

According to official regulatory documents, Flotral is only indicated for treating the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH), commonly known as an enlarged prostate. While research has examined its use in other related conditions, its formal approved indication is limited to BPH.

Q: What should I do if I feel dizzy after starting Flotral?

Regulatory warnings indicate that dizziness and a temporary loss of consciousness (syncope) are possible, especially when initiating treatment or standing up quickly. Official warnings describe resting by sitting or lying down if these symptoms occur. Individuals are cautioned against driving or operating heavy machinery until they are aware of the drug’s effects.

Q: What is the risk of a severe allergic reaction to Flotral?

Flotral is contraindicated (must not be used) in anyone with a known sensitivity to the active ingredient, alfuzosin, or other tablet components. Official information lists severe allergic reactions as a potential risk. Signs of a severe reaction can include rash, swelling of the face or throat, and difficulty breathing.

Q: Are there long-term risks associated with taking Flotral for many years?

Flotral is intended for continuous, long-term use to manage BPH symptoms. Long-term studies have examined how efficacy may be maintained. However, regulatory documents indicate that the full long-term safety data are not fully established, and monitoring for known risks like blood pressure effects and a complication called Intraoperative Floppy Iris Syndrome (IFIS) is necessary.

Q: Is Flotral the same as Tamsulosin?

No, Flotral and Tamsulosin are not the same drug. Flotral contains the active ingredient alfuzosin, while Tamsulosin is a different medication. Regulatory documents caution against combining Flotral with any other alpha-blocker due to the risk of dangerously low blood pressure.

Q: Can I take Flotral if I have low blood pressure?

Official warnings advise caution for individuals who have a history of symptomatic orthostatic hypotension (low blood pressure upon standing). Caution is also required for those who have previously experienced a significant hypotensive response to other alpha-blockers, as the drug is associated with a risk of low blood pressure, especially when initiating treatment.

Q: Is Flotral considered a high-risk medication?

Official labeling for Flotral highlights several specific, serious safety considerations that require emphasis. These include a potential for Priapism (a prolonged erection), Syncope (fainting), and a complication known as Intraoperative Floppy Iris Syndrome (IFIS), which is relevant if you need cataract surgery.

Q: How quickly should I expect Flotral to start working?

The official pharmacokinetic data describes how the medication is processed by the body. The maximum level of the drug's active ingredient in the bloodstream is reached approximately 8 hours after taking the extended-release tablet with a meal. This peak concentration is necessary for the drug to begin its intended action.

Q: Is it okay to drink alcohol while using Flotral?

Regulatory warnings state that combining Flotral with alcohol may increase the risk of developing orthostatic hypotension, which is low blood pressure that occurs when standing up. Official warnings advise avoiding or minimizing alcohol intake while using this medication.

Q: Can Flotral cause problems with sexual function?

Official documents list potential effects on sexual function, including the rare but serious risk of Priapism, which is a prolonged and often painful erection. Furthermore, some men in clinical studies experienced changes in ejaculation, such as ejaculatory dysfunction.

Q: How long does Flotral stay in my system?

Based on the drug's pharmacokinetic data, the apparent elimination half-life of the extended-release tablet is approximately 10 hours. This measurement describes the time it takes for the concentration of the medication in the body to be reduced by half.

Q: Can I stop taking Flotral suddenly if I feel better?

Official patient guidance indicates that Flotral is used to control BPH symptoms, but it is not a cure for the condition. Regulatory patient guidance advises against discontinuing therapy without prior discussion with a healthcare provider.

Q: Does Flotral affect my ability to drive?

Official warnings caution against engaging in potentially hazardous activities, such as driving or operating heavy machinery. This is due to the potential for common side effects like dizziness, lightheadedness, or fainting.

Q: Is it normal to feel a change in heart rate when taking Flotral?

Official clinical studies have observed a mean change in heart rate associated with the use of Flotral. Caution is specifically advised by regulatory documents for individuals who have a history of certain rapid or irregular heart rhythm conditions (tachyarrhythmia).

How to Store and Dispose of Flotral (Alfuzosin Extended-Release Tablets)

The storage and disposal of alfuzosin extended-release tablets must strictly follow official regulatory guidelines to maintain product quality and safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Environment	The container must be kept tightly closed and stored away from excess heat, moisture, and light.
Handling	The medicine must be kept from freezing and stored out of the reach of children.

---

Disposal Instructions

Unused or expired tablets should not be flushed down the toilet, as this product is not on the official government flush list. The preferred method of disposal is using a drug take-back program. If a program is unavailable, the tablets must be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag, and then discarded in the household trash. All identifying information must be removed from the packaging prior to disposal.